Live Breaking News & Updates on Osimertinib

Stay updated with breaking news from Osimertinib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLC

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.

....

United States , Jaime Schneider , Harvard Medical School , Thoracic Cancers , Massachusetts General Hospital , Egfr Mutant Non Small Cell Lung Cancer ,

Osimertinib With Chemo Gains FDA Approval for EGFR-Mutated NSCLC

Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy. ....

United States , Dave Fredrickson , Astra Zeneca , American Society Of Clinical Oncology , Dana Farber Cancer Institute , New England Journal , Oncology Business Unit , American Society , Targeted Therapy ,

Maintenance Osimertinib Demonstrates PFS Benefit in Stage III EGFR-Mutant NSCLC

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer. ....

United States , Suresh Ramalingam , Susan Galbraith , Winship Cancer Institute Of Emory University , World Health Organization , Oncology Research Development At Astrazeneca , Winship Cancer Institute , Emory University , South America , Oncology Research , Egfr Mutant Nsclc , Phase 3 Laura Trial Nct03521154 ,

Continued Investigations are Pertinent for FDA Approvals in the Treatment of Patients With EGFR-mutated NSCLC

Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more. ....

United States , Wadet Iams , Danielv Wakefield , Erina Gillaspie , Nagla Abdel Karim , Jason Porter , Vanderbilt Ingram Cancer Center , Research Institute In Memphis , University Of Virginia , Institutional Perspectives , Lung Cancer Disease Research Group , West Cancer Center , Research Institute , Egfr Tkis , Adaura Trial , Institutional Perspectives In Cancer , Egfr Mutations , Non Small Cell Lung Cancer ,

Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations. ....

Precision Medicine , Biomarker Testing , Non Small Cell Lung Cancer , Uncommon Egfr Mutations , Nccn Guidelines , Treatment Sequencing , Exon 20 Insertions , Biomarker Driven Therapy , Egfr Mutations ,